Kedalion Therapeutics
Kedalion Therapeutics is a clinical-stage biotechnology company that developed AcuStream, a preservative-free electromechanical device for precise topical ocular drug delivery, targeting front-of-eye therapies. The company was acquired by Novartis in June 2022.
- Company typePrivate
- Founded2015
- HeadquartersMenlo Park, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kedalion Therapeutics does
Kedalion Therapeutics is a clinical-stage biotechnology company that developed the AcuStream™ platform, a preservative-free, electromechanical topical ocular delivery device designed to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. Founded in 2015 and headquartered in Menlo Park, California, the company targeted front-of-eye therapies with documented clinical proof-of-concept studies, with stated potential application to dry eye disease treatments including use with Novartis's Xiidra (lifitegrast ophthalmic solution) 5%. The platform is differentiated by its electromechanical mechanism, preservative-free formulation, and dosing precision relative to conventional eye drop delivery.
The company operated with a small team of 1-10 employees and pursued a partnership- and licensing-oriented business model rather than direct commercial sales. Pre-acquisition, Kedalion's only disclosed strategic customer and lead investor was Novartis, which led the Series B financing in November 2021 and held an exclusive option to acquire the company. On June 30, 2022, Novartis exercised that option, acquiring Kedalion and integrating AcuStream into its ophthalmics portfolio for use with both existing and future front-of-eye therapies.
Post-acquisition, distribution leverages Novartis's global pharmaceutical channels targeting healthcare providers and ophthalmology practices. The company had no disclosed product revenue, operating as a pre-commercial development-stage entity. Leadership included co-founder and CEO Mark Blumenkranz, founder and CTO Ehud Ivri, COO and Executive Vice President Casey Dougan, and CFO Mark Murray. Initial funding came from Lagunita BioSciences in 2018, with Novartis Venture Fund joining as lead investor in 2021.
Kedalion Therapeutics firmographics
Firmographics- Name
- Kedalion Therapeutics
- Legal name
- Kedalion Therapeutics
- Website
- https://kedalionthera.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Kedalion Therapeutics is a clinical-stage biotechnology company that developed AcuStream, a preservative-free electromechanical device for precise topical ocular drug delivery, targeting front-of-eye therapies. The company was acquired by Novartis in June 2022.
- Ownership category
- akta.pro rank
Kedalion Therapeutics industry classification
Industry- Product category
- Ophthalmic Drug Delivery Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)
- akta.pro primary industry
- Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
- akta.pro secondary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
Keywords
Where Kedalion Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kedalion Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Drug Delivery Technology Licensing/Acquisition: Prior to acquisition, Kedalion developed its AcuStream technology for licensing to pharmaceutical partners. Novartis acquired the company in June 2022, integrating the technology into its ophthalmics portfolio for use with existing and investigational front-of-eye therapies.
Go-to-market motion1 record
Distribution channels1 record
Kedalion Therapeutics product offering
Product offeringCore offering
Kedalion Therapeutics develops the AcuStream™ platform, a preservative-free, electromechanical topical ocular delivery device designed to facilitate precise dosing and accurate delivery of topical ophthalmic medications to the eye. The technology is intended for front-of-eye therapies and is being developed for use with existing and future ophthalmic medications such as Xiidra (lifitegrast ophthalmic solution) 5% for dry eye disease treatment.
Product overview
Kedalion Therapeutics is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, California. Their primary product is the AcuStream™ platform, an electromechanical topical ocular delivery device designed for precise dosing of ophthalmic medications. Novartis acquired Kedalion Therapeutics and its AcuStream technology in June 2022, integrating it into their ophthalmics portfolio. The technology is being developed for potential use with front-of-eye therapies including Xiidra® (lifitegrast ophthalmic solution) 5% for dry eye disease treatment.
Differentiator
Problem solved
Functional benefit
Brands
- AcuStream: A novel topical ocular delivery device designed to facilitate dosing precision with the potential to support the delivery of front-of-eye therapies and help patient comfort during therapy administration. The platform is a preservative-free, electromechanical topical ocular delivery device.
Products and services
- AcuStream™ A preservative-free, electromechanical topical ocular delivery device designed to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. The platform is intended for front-of-eye therapies and aims to help patient comfort during therapy administration.
Companies that use Kedalion Therapeutics
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Kedalion Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Kedalion Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
Kedalion Therapeutics competitors and assessment
Company assessmentDirect peers
- Eyenovia: Eyenovia is developing microdose array-printing delivery platforms for front-of-eye therapies. It is a direct competitor in novel electromechanical/microfluidic ocular drug delivery targeting similar ophthalmology indications such as dry eye and mydriasis.
- Ocular Therapeutix: Ocular Therapeutix develops sustained-release intracanalicular and punctal plug inserts for ophthalmic drug delivery. It is directly comparable as a company creating novel front-of-eye drug delivery formats to improve compliance and tolerability versus conventional eye drops.
- Oyster Point Pharma: Oyster Point Pharma developed and commercialized Tyrvaya, a nasal spray for dry eye disease, and was acquired by Viatris. It is comparable as a clinical-stage-to-commercial ophthalmology company focused on novel delivery routes for front-of-eye therapies.
Emerging players
- Aldeyra Therapeutics: Aldeyra is developing novel small-molecule therapies for dry eye disease and other inflammatory ocular conditions. It is comparable as a clinical-stage ophthalmology company whose products could be paired with delivery platforms like AcuStream.
- SilkTech Biopharmaceuticals: SilkTech is developing silk protein-based ophthalmic drug formulations, including preservative-free formulations. It is comparable as a clinical-stage innovator addressing the same preservative-free, front-of-eye comfort and tolerability pain points AcuStream targets.
- Mystic Pharmaceuticals: Mystic Pharmaceuticals develops unit-dose, preservative-free delivery platforms for ophthalmic and other liquid medications. It is comparable as a company building novel preservative-free ocular and nasal delivery formats aimed at dosing precision and patient comfort.
Broad incumbents
- Bausch + Lomb: Bausch + Lomb is a major ophthalmology incumbent with a broad portfolio of eye drops, surgical products, and consumer vision care. It is comparable as both a potential competitor and a potential partner/licensor for novel ocular delivery devices targeting the dry-eye and front-of-eye markets.
- Alcon: Alcon is the largest dedicated ophthalmology company globally, with a portfolio spanning surgical, pharmaceutical, and consumer eye care. It is comparable as an incumbent that competes with the AcuStream-plus-Xiidra value proposition in dry eye and could acquire or partner with delivery-platform innovators.
- Allergan / AbbVie: Allergan (now part of AbbVie) markets Restasis and other leading dry-eye and ophthalmology products. It is comparable as a major competitor in the dry-eye pharmaceutical space whose commercial success directly affects the value of pairing AcuStream with Xiidra.
Regional players
- Glaukos Corporation: Glaukos is an ophthalmic medical technology company best known for MIGS devices and is expanding into sustained-release drug delivery. It is comparable as a publicly traded ophthalmic device innovator pursuing novel front-of-eye and sustained-release delivery approaches, primarily serving the U.S. ophthalmology market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Kedalion Therapeutics social profiles
Digital presenceKedalion Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kedalion Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Kedalion Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kedalion Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kedalion Therapeutics
What does Kedalion Therapeutics do?
Kedalion Therapeutics develops the AcuStream™ platform, a preservative-free, electromechanical topical ocular delivery device designed to facilitate precise dosing and accurate delivery of topical ophthalmic medications to the eye. The technology is intended for front-of-eye therapies and is being developed for use with existing and future ophthalmic medications such as Xiidra (lifitegrast ophthalmic solution) 5% for dry eye disease treatment.
Is Kedalion Therapeutics a public or private company?
Kedalion Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Kedalion Therapeutics founded?
Kedalion Therapeutics was founded in 2015. It employs 1 to 10 people.
Where is Kedalion Therapeutics based?
Kedalion Therapeutics is headquartered in Menlo Park, United States, in the North America region.
How does Kedalion Therapeutics make money?
One revenue line is on record: drug Delivery Technology Licensing/Acquisition.
Who are Kedalion Therapeutics's main competitors?
Direct peers on record are Eyenovia, Ocular Therapeutix and Oyster Point Pharma. Emerging players are Aldeyra Therapeutics, SilkTech Biopharmaceuticals and Mystic Pharmaceuticals. Broad incumbents are Bausch + Lomb, Alcon and Allergan / AbbVie. Glaukos Corporation is listed as a regional player.
Does Kedalion Therapeutics have an API?
No public API is recorded for Kedalion Therapeutics.
What industry is Kedalion Therapeutics in?
Kedalion Therapeutics's product category is Ophthalmic Drug Delivery Devices. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 339115 and its SIC code is 3841.